SR9009 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-04 and is reviewed periodically as new material appears.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Wiskott–Aldrich syndrome (WAS) patients also present with eczema, autoimmune manifestations, recurrent bacterial infections, and lymphoma. In autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), autoimmunity and infections coexist: organ-specific autoimmune manifestations (e.g., hypoparathyroidism and adrenocortical failure) and chronic mucocutaneous candidiasis. Finally, IgA deficiency is sometimes associated with developing autoimmune and atopic phenomena.
The protest demonstration soon erupted into a riot; the crowd took to the streets, placing the capital, like Timișoara, in turmoil. Members of the crowd spontaneously began shouting anti-Ceaușescu slogans, which spread and became chants: "Jos dictatorul!" ("Down with the dictator"), "Moarte criminalului!" ("Death to the criminal"), "Noi suntem poporul, jos cu dictatorul!" ("We are the people, down with the dictator"), "Ceaușescu cine ești?/Criminal din Scornicești" ("Ceaușescu, who are you? A criminal from Scornicești").
== Chemical and physical properties == Glucose forms white or colorless solids that are highly soluble in water and acetic acid but poorly soluble in methanol and ethanol. They melt at 146 °C (295 °F) (α) and 150 °C (302 °F) (beta), decompose starting at 188 °C (370 °F) with release of various volatile products, ultimately leaving a residue of carbon. With six carbon atoms, it is classed as a hexose, a subcategory of the monosaccharides. d-Glucose is one of the sixteen aldohexose stereoisomers. The d-isomer, d-glucose, also known as dextrose, occurs widely in nature, but the l-isomer, l-glucose, does not. Glucose can be obtained by hydrolysis of carbohydrates such as milk sugar (lactose), cane sugar (sucrose), maltose, cellulose, glycogen, etc. Dextrose is commonly commercially manufactured from starches, such as corn starch in the US and Japan, from potato and wheat starch in Europe, and from tapioca starch in tropical areas. The manufacturing process uses hydrolysis via pressurized steaming at controlled pH in a jet followed by further enzymatic depolymerization. Unbonded glucose is one of the main ingredients of honey. The term "dextrose" is often used in a clinical (related to patient's health status) or nutritional context (related to dietary intake, such as food labels or dietary guidelines), while "glucose" is used in a biological or physiological context (chemical processes and molecular interactions), but both terms refer to the same molecule, specifically D-glucose.
=== Inherited forms === (G71.0) Dystrophies (or muscular dystrophies) are a subgroup of myopathies characterized by muscle degeneration and regeneration. Clinically, muscular dystrophies are typically progressive, because the muscles' ability to regenerate is eventually lost, leading to progressive weakness and often leading to use of a wheelchair and eventually death, usually related to respiratory weakness. (G71.1) Myotonia Neuromyotonia (G71.2) The congenital myopathies do not show evidence for either a progressive dystrophic process (i.e., muscle death) or inflammation, but instead characteristic microscopic changes are seen in association with reduced contractile ability of the muscles. Congenital myopathies include, but are not limited to: (G71.2) nemaline myopathy (characterized by presence of "nemaline rods" in the muscle), (G71.2) multi/minicore myopathy (characterized by multiple small "cores" or areas of disruption in the muscle fibers), (G71.2) centronuclear myopathy (or myotubular myopathy) (in which the nuclei are abnormally found in the center of the muscle fibers), a rare muscle wasting disorder.
Pyrimidine oxygenase (EC 1.14.99.46, gene RutA) is an enzyme characterised from Escherichia coli with systematic name uracil,FMNH2:oxygen oxidoreductase (uracil hydroxylating, ring-opening). It catalyses two related oxidation reactions which act on pyrimidine nucleobases. The overall effect of the first example is to convert uracil to (Z)-3-ureidoacrylic acid with molecular oxygen as the oxidant and flavin mononucleotide (FMN) as a cofactor. The enzyme also requires nicotinamide adenine dinucleotide (NADH):
Sources: en.wikipedia.org
== Treatment == There are many causes of necrosis, and as such treatment is based upon how the necrosis came about. Treatment of necrosis typically involves two distinct processes: Usually, the underlying cause of the necrosis must be treated before the dead tissue itself can be dealt with.
The World Health Organization's ICD-11 has replaced the categorical classification of personality disorders in the ICD-10 with a dimensional model containing a unified personality disorder with severity specifiers, along with specifiers for prominent personality traits or patterns. Among these is the borderline pattern, which is similar to the diagnosis of BPD. The borderline pattern specifier is described in the ICD-11 as applicable to "individuals whose pattern of personality disturbance is characterized by a pervasive pattern of instability of interpersonal relationships, self-image, and affects, and marked impulsivity". Borderline personality disorder has been found to be primarily associated with the ICD-11 trait domains of Negative Affectivity and Disinhibition, reflecting core features such as emotional instability and impulsivity. Previously, the ICD-10 had identified a condition akin to BPD, termed Emotionally unstable personality disorder (EUPD). The ICD-11 borderline pattern diagnosis has been criticized for being "indissociable" from negative affectivity upon undergoing regression and factor analyses. A study has found that the diagnosis of borderline pattern does not provide additional insight beyond what is captured by other specifiers, positing that it may be redundant.
==== Astrocytes and blood oxygen levels ==== The Sur lab has discovered novel and critical roles for astrocytes in brain function. By high resolution imaging in the intact visual cortex, they showed that astrocytes have tuned calcium responses to visual stimuli that are mediated importantly via glutamate transporters on astrocyte processes that surround synapses, and they influence local blood flow and hence the hemodynamic signals that underlie brain imaging methods such as fMRI. Role of astrocytes in information processing and plasticity Astrocytes are also activated by neuromodulators such as acetylcholine and norepinephrine, and Sur and coworkers showed that cholinergic inputs to cortex act via astrocytes to alter the strength of excitatory synapses and implement plasticity of neuronal responses. Furthermore, astrocyte GABA transporters regulate extrasynaptic GABA and influence population coding of visual information by V1 neurons. Astrocyte calcium signaling influences excitatory drive to inhibitory neurons, thereby enabling astrocytes to modulate excitatory-inhibitory balance in neuronal V1 circuits. Astrocytes and learning Glutamate transporters on astrocytes regulate developmental plasticity in visual cortex. Gene expression (of glutamate and GABA transporters) in cortical astrocytes is modulated by learning, and astrocytes thus crucially shape cortical neuronal activity underlying learned behavior.
=== Applications === A large area of interest in nanomedicine is the transdermal patch because of the possibility of a painless application of therapeutic agents with very few side effects. Transdermal patches have been limited to administer a small number of drugs, such as nicotine, because of the limitations in permeability of the skin. Development of techniques that increase skin permeability has led to more drugs that can be applied via transdermal patches and more options for patients. Increasing the permeability of skin allows nanoparticles to penetrate and target cancer cells. Nanoparticles along with multi-modal imaging techniques have been used as a way to diagnose cancer non-invasively. Skin with high permeability allowed quantum dots with an antibody attached to the surface for active targeting to successfully penetrate and identify cancerous tumours in mice. Tumour targeting is beneficial because the particles can be excited using fluorescence microscopy and emit light energy and heat that will destroy cancer cells.
An electrocardiogram (ECG) is a recording of the heart's electrical activity, acquired using electrodes placed on the skin. The taking of an ECG is an important part of the workup of an AMI, and ECGs are often not just taken once but may be repeated over minutes to hours, or in response to changes in signs or symptoms. ECG readouts produce a waveform with different labeled features. In addition to a rise in biomarkers, a rise in the ST segment, changes in the shape or flipping of T waves, new Q waves, or a new left bundle branch block can be used to diagnose an AMI. In addition, ST elevation can be used to diagnose an ST segment myocardial infarction (STEMI). A rise must be new in V2 and V3 ≥2 mm (0.2 mV) for males or ≥1.5 mm (0.15 mV) for females or ≥1 mm (0.1 mV) in two other adjacent chest or limb leads. ST elevation is associated with infarction, and may be preceded by changes indicating ischemia, such as ST depression or inversion of the T waves. Abnormalities can help differentiate the location of an infarct, based on the leads that are affected by changes. Early STEMIs may be preceded by peaked T waves. Other ECG abnormalities relating to complications of acute myocardial infarctions may also be evident, such as atrial or ventricular fibrillation.
Sources: en.wikipedia.org
== Nomenclature == This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-2-aminoadipate-6-semialdehyde:NAD(P)+ 6-oxidoreductase. Other names in common use include:
==== Mechanical properties ==== DBHA exhibits shear thinning behaviour and at low strains, storage and loss moduli are independent of strain but past a critical strain, the hydrogel yields and is transformed from a solid to a liquid.
Among those from the world of politics to be recognised in the 2024 Birthday Honours is former prime minister Gordon Brown, who is made a Companion of Honour, and former MP Wayne David, who receives a knighthood. 16 June – Grant StClair-Armstrong, the Reform UK candidate for North West Essex, resigns from the party after historic blog posts emerge in which he urged people to vote for the British National Party. ITV Wales holds an election debate between senior figures from the three main political parties in Wales; David TC Davies (Conservative), Jo Stevens (Labour) and Liz Saville Roberts (Plaid Cymru). 17 June – Nigel Farage launches Reform UK's election manifesto, which he describes as a contract, and which chiefly proposes a freeze on non-essential immigration. Lord Cashman is suspended from the Parliamentary Labour Party for describing Rosie Duffield as "frit or lazy" in a social media post for withdrawing from hustings meetings over concerns for her safety. BBC Sounds launches an Election 2024 livestream, bringing together all the election news and programming, such as Newscast, Today, Question Time and Sunday with Laura Kuenssberg. The livestream is scheduled to run until 8 July. 18 June – LBC's Nick Ferrari presents the first of two editions of Britain's Next PM, a phone-in giving listeners the opportunity to speak to Keir Starmer and Rishi Sunak, with Starmer appearing on the first edition and Sunak the following day. The deadline for people wishing to register to vote in time for the 2024 general election expires at 23:59.
Polonium is now usually obtained by irradiating bismuth with high-energy neutrons or protons. In 1934, an experiment showed that when natural 209Bi is bombarded with neutrons, 210Bi is created, which then decays to 210Po via beta-minus decay. By irradiating certain bismuth salts containing light element nuclei such as beryllium, a cascading (α,n) reaction can also be induced to produce 210Po in large quantities. The final purification is done pyrochemically followed by liquid-liquid extraction techniques. Polonium may now be made in milligram amounts in this procedure which uses high neutron fluxes found in nuclear reactors. Only about 100 grams are produced each year, practically all of it in Russia, making polonium exceedingly rare. This process can cause problems in lead-bismuth based liquid metal cooled nuclear reactors such as those used in the Soviet Navy's K-27. Measures must be taken in these reactors to deal with the unwanted possibility of 210Po being released from the coolant. The longer-lived isotopes of polonium, 208Po and 209Po, can be formed by proton or deuteron bombardment of bismuth using a cyclotron. Other more neutron-deficient and more unstable isotopes can be formed by the irradiation of platinum with carbon nuclei.
In this case, the objective is the creation of chassis genomes based on necessary genes and other required DNA sequences rather than the design of metabolic or regulatory pathways based on abstract criteria.
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
Research-grade SR9009 is typically stored frozen at about minus twenty degrees Celsius, protected from light and moisture. Stock solutions are often kept in aliquots to avoid repeated freeze-thaw cycles. Specific storage conditions should follow the supplier's documentation.